Temple University Hospital and Fox Chase Cancer Center are the only two sites in Philadelphia that participated in an international phase I, randomized clinical trial which tested the drug guadecitabine (SGI-110) in Myelodysplastic ...
Aug 18, 2015
0
24
A new study by researchers at University of California, San Diego School of Medicine reveals a protein's critical - and previously unknown—role in the development and progression of acute myeloid leukemia (AML), a fast-growing ...
Jul 23, 2015
0
21
The University of Texas MD Anderson Cancer Center and Amgen have announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a "bridge" ...
Jan 13, 2015
0
5
An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) - a poor-prognosis group with few options - report investigators ...
Dec 8, 2014
0
0
Treating hematologic malignancies upfront with a combination of drugs based on the vulnerabilities of tumors as they evolve may be a viable strategy to avoid drug resistance, according to data presented at the American Association ...
Sep 23, 2014
0
0
Patients with a variety of hematological, or blood, cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain ...
Apr 8, 2014
0
0
Nearly half of patients with the most common form of adult leukemia are said to have normal chromosomes but appear instead to have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment, ...
Mar 29, 2014
0
0
Using genetic information initially uncovered in fruit fly studies, scientists have developed a unique therapeutic strategy that stops an aggressive and deadly form of leukemia in laboratory models of the disease.
Dec 16, 2013
0
0
The resistance of some cancers to the cell-killing effects of radiation therapy may be due to abnormalities in the mitochondria – the cellular structures responsible for generating energy, according to an international ...
Nov 25, 2013
0
0
A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival ...
Apr 17, 2013
0
0
